# EDGAR Filing Document

**Accession Number:** 0001711279
**File Stem:** 0001801385-26-000002
**Filing Date:** 2026-3
**Character Count:** 9086
**Document Hash:** 309a826385be1f2ea8bee6d4aff6d3e0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001801385-26-000002.hdr.sgml**: 20260303

**ACCESSION NUMBER**: 0001801385-26-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260227

**FILED AS OF DATE**: 20260303

**DATE AS OF CHANGE**: 20260303

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** ROMANO KATHRYN
- **CENTRAL INDEX KEY:** 0001801385

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38210
- **FILM NUMBER:** 26717516

**MAIL ADDRESS:**
- **STREET 1:** C/O KRYSTAL BIOTECH, INC.
- **STREET 2:** 2100 WHARTON STREET, SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Romano Kathryn
- **DATE OF NAME CHANGE:** 20200128
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Krystal Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001711279
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 821080209
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2100 WHARTON STREET
- **STREET 2:** SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203
- **BUSINESS PHONE:** (412) 586-5830

**MAIL ADDRESS:**
- **STREET 1:** 2100 WHARTON STREET
- **STREET 2:** SUITE 701
- **CITY:** PITTSBURGH
- **STATE:** PA
- **ZIP:** 15203

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>ROMANO KATHRYN<br><sub>(Last) (First) (Middle)</sub><br>C/O KRYSTAL BIOTECH, INC.<br>2100 WHARTON STREET, SUITE 701<br><sub>(Street)</sub><br>PITTSBURGH, PA 15203<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-02-27 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_Chief Accounting Officer_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>Krystal Biotech, Inc. [ KRYS ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-02-27 |  | M |  | 7500<sup>(1)</sup> | A | $0 | 26068 | D |  |
| Common Stock | 2026-02-27 |  | F |  | 3262<sup>(2)</sup> | D | 275.64<sup>(3)</sup> | 22806 | D |  |
| Common Stock | 2026-02-27 |  | M |  | 550<sup>(4)</sup> | A | $0 | 23356 | D |  |
| Common Stock | 2026-02-27 |  | F |  | 240<sup>(5)</sup> | D | 275.64<sup>(3)</sup> | 23116 | D |  |
| Common Stock | 2026-03-02 |  | S |  | 750<sup>(6)</sup> | D | $267.60 | 22366 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Performance Stock Units | <sup>(1)</sup> | 2026-02-27 |  | M |  |  | 7500 | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 7500 | $0 | 0 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | 2026-02-27 |  | M |  |  | 550 | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 550 | $0 | 1650 | D |  |
| Stock Option (Right to Buy) | $275.64 | 2026-02-27 |  | A |  | 13575 |  | <sup>(7)</sup> | 2036-02-26 | Common Stock | 13575 | $0 | 13575 | D |  |
| Restricted Stock Units | <sup>(8)</sup> | 2026-02-27 |  | A |  | 5442<sup>(9)</sup> |  | <sup>(10)</sup> | <sup>(10)</sup> | Common Stock | 5442 | $0 | 5442 | D |  |

---

### Footnotes:

(1) 15,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 7,500 PSUs, vested on February 27, 2026.

(2) Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 7,500 RSUs on February 27, 2026.

(3) The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.

(4) 2,200 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 550 RSUs, vesting on February 27, 2026.

(5) Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 550 RSUs on February 27, 2026.

(6) The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2025. The Rule 10b5-1 trading plan terminated upon completion of the sale of the shares of the Company's common stock reported on this Form 4, which represented the completion of all sales of the Company's common stock subject to the Rule 10b5-1 trading plan.

(7) The stock options vest in four equal annual installments beginning on February 27, 2027.

(8) Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.

(9) The number of RSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming the Reporting Person's continued service to the Company on all applicable vesting dates.

(10) The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.

**Signature:** /s/ Kathryn Romano  
**Date:** 2026-03-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**